DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Open accessAbstract
Biomarkers are urgently needed for the diagnosis and monitoring of disease progression in Parkinson's disease. Both DJ-1 and alpha-synuclein, two proteins critically involved in Parkinson's disease pathogenesis, have been tested as disease biomarkers in several recent studies with inconsistent results. These have been largely due to variation in the protein species detected by different antibodies, limited numbers of patients in some studies, or inadequate control of several important variables. In this study, the nature of DJ-1 and alpha-synuclein in human cerebrospinal fluid was studied by a combination of western blotting, gel filtration and mass spectrometry. Sensitive and quantitative Luminex assays detecting most, if not all, species of DJ-1 and alpha-synuclein in human cerebrospinal fluid were established. Cerebrospinal fluid concentrations of DJ-1 and alpha-synuclein from 117 patients with Parkinson's disease, 132 healthy individuals and 50 patients with Alzheimer's disease were analysed using newly developed, highly sensitive Luminex technology while controlling for several major confounders. A total of 299 individuals and 389 samples were analysed. The results showed that cerebrospinal fluid DJ-1 and alpha-synuclein levels were dependent on age and influenced by the extent of blood contamination in cerebrospinal fluid. Both DJ-1 and alpha-synuclein levels were decreased in Parkinson's patients versus controls or Alzheimer's patients when blood contamination was controlled for. In the population aged > or = 65 years, when cut-off values of 40 and 0.5 ng/ml were chosen for DJ-1 and alpha-synuclein, respectively, the sensitivity and specificity for patients with Parkinson's disease versus controls were 90 and 70% for DJ-1, and 92 and 58% for alpha-synuclein. A combination of the two markers did not enhance the test performance. There was no association between DJ-1 or alpha-synuclein and the severity of Parkinson's disease. Taken together, this represents the largest scale study for DJ-1 or alpha-synuclein in human cerebrospinal fluid so far, while using newly established sensitive Luminex assays, with controls for multiple variables. We have demonstrated that total DJ-1 and alpha-synuclein in human cerebrospinal fluid are helpful diagnostic markers for Parkinson's disease, if variables such as blood contamination and age are taken into consideration.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Lower cerebrospinal fluid αSyn could distinguish Parkinson's disease from Alzheimer's disease patients.
“several studies including our own have shown that lower CSF αSyn could distinguish PD from AD patients [81, 97].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · see citing works
Levodopa and the Progression of Parkinson's Disease
The Parkinson Study Group (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,844 · see citing works
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works
Multiplexed particle-based flow cytometric assays
Vignali, D. A. A. (2000) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00238-6 · Cited by 916 · see citing works
El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715 · see citing works
Oxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases
Choi, J., Sullards, M. C., Olzmann, J. A., Rees, H. D., Weintraub, S. T., Bostwick, D. E., Gearing, M., Levey, A. I., Chin, L., & Li, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509079200 · Cited by 482 · see citing works
Galvin, J. E., Lee, V. M. ‐., & Trojanowski, J. Q. (2001) · Archives of Neurology · doi:10.1001/archneur.58.2.186 · Cited by 466 · see citing works
Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425 · see citing works
Proteasomal Inhibition by α-Synuclein Filaments and Oligomers
Lindersson, E., Beedholm, R., Højrup, P., Moos, T., Gai, W., Hendil, K. B., & Jensen, P. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306390200 · Cited by 399 · see citing works
Self-citationMollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382 · see citing works
Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., Abbruzzese, G., & Tabaton, M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01153-8 · Cited by 363 · see citing works
duPont, N. C., Wang, K., Wadhwa, P. D., Culhane, J. F., & Nelson, E. L. (2005) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2005.03.005 · Cited by 319 · see citing works
Alpha-synuclein and Parkinson's disease
Lücking, C. B., & Brice, A. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000671 · Cited by 279 · see citing works
The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy
Lee, P. H., Lee, G., Park, H. J., Bang, O. Y., Joo, I. S., & Huh, K. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0427-9 · Cited by 242 · see citing works
Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?
Öhrfelt, A., Grognet, P., Andreasen, N., Wallin, A., Vanmechelen, E., Blennow, K., & Zetterberg, H. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.015 · Cited by 198 · see citing works
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease
Waragai, M., Wei, J., Fujita, M., Nakai, M., Ho, G. J., Masliah, E., Akatsu, H., Yamada, T., & Hashimoto, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.011 · Cited by 195 · see citing works
Plasma α-synuclein is decreased in subjects with Parkinson's disease
Li, Q., Mok, S. S., Laughton, K. M., McLean, C., Cappai, R., Masters, C. L., Culvenor, J. G., & Horne, M. K. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.12.006 · Cited by 160 · see citing works
Progressive supranuclear palsy: where are we now?
Burn, D. J., & Lees, A. J. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00161-8 · Cited by 137 · see citing works
Mollenhauer, B., Trenkwalder, C., von Ahsen, N., Bibl, M., Steinacker, P., Brechlin, P., Schindehütte, J., Poser, S., Wiltfang, J., & Otto, M. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000094871 · Cited by 131 · see citing works
Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease
Waragai, M., Nakai, M., Wei, J., Fujita, M., Mizuno, H., Ho, G. J., Masliah, E., Akatsu, H., Yokochi, F., & Hashimoto, M. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.08.010 · Cited by 113 · see citing works
Secretion of DJ-1 into the serum of patients with Parkinson's disease
Maita, C., Tsuji, S., Yabe, I., Hamada, S., Ogata, A., Maita, H., Iguchi‐Ariga, S. M. M., Sasaki, H., & Ariga, H. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.11.027 · Cited by 94 · see citing works
Cerebrospinal Fluid α-Synuclein Does Not Discriminate Between Dementia Disorders
Spies, P. E., Melis, R. J. F., Sjögren, M. J. C., Rikkert, M. G. M. O., & Verbeek, M. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0955 · Cited by 93 · see citing works
Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease
Michell, A. W., Luheshi, L. M., & Barker, R. A. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.02.030 · Cited by 92 · see citing works
DJ‐1 is present in a large molecular complex in human brain tissue and interacts with α‐synuclein
Meulener, M. C., Graves, C. L., Sampathu, D. M., Armstrong‐Gold, C. E., Bonini, N. M., & Giasson, B. I. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03145.x · Cited by 71 · see citing works
Platelet α- and γ-synucleins in Parkinson's disease and normal control subjects
Li, Q.-X., Campbell, B. C. V., McLean, C., Thyagarajan, D., Gai, W.-P., Kapsa, R. M. I., Beyreuther, K. T., Masters, C. L., & Culvenor, J. G. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4406 · Cited by 49 · see citing works
LOCALIZATION OF DOPAMINE RECEPTOR SUBTYPES IN SYSTEMIC ARTERIES
Amenta, F., Barili, P., Bronzetti, E., Felici, L., Mignini, F., & Rícci, A. (2000) · Clinical and Experimental Hypertension · doi:10.1081/ceh-100100077 · Cited by 49 · see citing works
Identification of novel proteins affected by rotenone in mitochondria of dopaminergic cells
Jin, J., Davis, J., Zhu, D. C., Kashima, D. T., Leroueil, M., Pan, C., Montine, K. S., & Zhang, J. (2007) · BMC Neuroscience · doi:10.1186/1471-2202-8-67 · Cited by 48 · see citing works
Self-citationDetermination of α‐synuclein concentration in human plasma using ELISA
Fjorback, W. A., Varming, K., & Jensen, H. P. (2007) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510601161497 · Cited by 46 · see citing works
Westerlund, M., Belin, A. C., Anvret, A., Håkansson, A. S., Nissbrandt, H., Lind, C., Sydow, O., Olson, L., & Galter, D. (2008) · The FASEB Journal · doi:10.1096/fj.08-110148 · Cited by 42 · see citing works
Liu, J., Hong, Z., Ding, J., Liu, J., Zhang, J., & Chen, S. (2008) · Journal of Proteome Research · doi:10.1021/pr7007779 · Cited by 41 · see citing works
Self-citationNural, H. F., He, P., Beach, T. G., Sue, L. I., Xia, W., & Shen, Y. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-23 · Cited by 36 · see citing works
van Geel, W. J. A., Abdo, W. F., Melis, R. J. F., Williams, S., Bloem, B. R., & Verbeek, M. M. (2007) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2007.09.021 · Cited by 32 · see citing works
Hong, Z., Zhang, Q.-Y., Liu, J., Wang, Z., Zhang, Y., Xiao, Q., Lü, J., Zhou, H.-Y., & Chen, S.-D. (2009) · Journal of Proteome Research · doi:10.1021/pr801052v · Cited by 19 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446 · see citing works
Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473 · see citing works
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374 · see citing works
Gao, H.-M., Zhou, H., Zhang, F., Wilson, B. C., Kam, W., & Hong, J.-S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3732-10.2011 · Cited by 369 · see citing works
del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.46 · Cited by 343 · see citing works
Alpha‐Synuclein as a Biomarker for Parkinson's Disease
Atik, A., Stewart, T., & Zhang, J. (2016) · Brain Pathology · doi:10.1111/bpa.12370 · Cited by 311 · see citing works
Self-citationNilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265 · see citing works
Alpha synuclein is transported into and out of the brain by the blood-brain barrier
Sui, Y.-T., Bullock, K. M., Erickson, M. A., Zhang, J., & Banks, W. A. (2014) · Peptides · doi:10.1016/j.peptides.2014.09.018 · Cited by 212 · see citing works
Self-citationCerebrospinal fluid biomarkers in Parkinson disease
Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., & Calabresi, P. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.10 · Cited by 209 · see citing works
Shi, M., Kovac, A., Korff, A., Cook, T. J., Ginghina, C., Bullock, K. M., Yang, L., Stewart, T., Zheng, D., Aro, P., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.04.003 · Cited by 206 · see citing works
Self-citationPicca, A., Guerra, F., Calvani, R., Romano, R., Coelho-Júnior, H. J., Bucci, C., & Marzetti, E. (2021) · Biomolecules · doi:10.3390/biom11101508 · Cited by 189 · see citing works
Jurado-Coronel, J. C., Cabezas, R., Ávila Rodríguez, M. F., Echeverria, V., García-Segura, L. M., & Barreto, G. E. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.09.002 · Cited by 180 · see citing works
Yanamandra, K., Gruden, M. A., Casaite, V., Meskys, R., Forsgren, L., & Morozova-Roche, L. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018513 · Cited by 171 · see citing works
Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Boström, F., Hansson, O., & Nielsen, H. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053250 · Cited by 141 · see citing works
Tateno, F., Sakakibara, R., Kawai, T., Kishi, M., & Murano, T. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31823899cc · Cited by 121 · see citing works
Reduced CSF p-Tau <sub>181</sub> to Tau ratio is a biomarker for FTLD-TDP
Hu, W. T., Watts, K., Grossman, M., Glass, J., Lah, J. J., Hales, C., Shelnutt, M., Van Deerlin, V., Trojanowski, J. Q., & Levey, A. I. (2013) · Neurology · doi:10.1212/01.wnl.0000436625.63650.27 · Cited by 113 · see citing works
Altered CSF Orexin and α-Synuclein Levels in Dementia Patients
Wennström, M., Londos, E., Minthon, L., & Nielsen, H. M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111655 · Cited by 104 · see citing works
α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment
Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95 · see citing works
Self-citationBiomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92 · see citing works
van Dijk, K. D., Bidinosti, M., Weiss, A., Raijmakers, P., Berendse, H. W., & van de Berg, W. D. J. (2014) · European Journal of Neurology · doi:10.1111/ene.12176 · Cited by 88 · see citing works
Increased CSF α‐synuclein levels in Alzheimer's disease: Correlation with tau levels
Slaets, S., Vanmechelen, E., Le Bastard, N., Decraemer, H., Vandijck, M., Martin, J., De Deyn, P. P., & Engelborghs, S. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.004 · Cited by 85 · see citing works
Basal lamina changes in neurodegenerative disorders
Nguyen, B., Bix, G., & Yao, Y. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00502-y · Cited by 75 · see citing works
Synaptic proteins in CSF relate to Parkinson’s disease stage markers
Bereczki, E., Bogstedt, A., Höglund, K., Tsitsi, P., Brodin, L., Ballard, C., Svenningsson, P., & Aarsland, D. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0008-2 · Cited by 72 · see citing works
Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., et al. (2023) · Journal of Parkinson’s Disease · doi:10.3233/jpd-223433 · Cited by 70 · see citing works
Self-citationThe relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
for the Dominantly Inherited Alzheimer Network (DIAN), Twohig, D., Rodriguez-Vieitez, E., Sando, S. B., Berge, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., Patra, K., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0624-z · Cited by 68 · see citing works
Cilento, E. M., Jin, L., Stewart, T., Shi, M., Sheng, L., & Zhang, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14635 · Cited by 60 · see citing works
Self-citationVergallo, A., Bun, R., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Cavedo, E., Lamari, F., Habert, M., Dubois, B., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3053 · Cited by 59 · see citing works
Majbour, N. K., Chiasserini, D., Vaikath, N. N., Eusebi, P., Tokuda, T., van de Berg, W., Parnetti, L., Calabresi, P., & El-Agnaf, O. M. A. (2017) · Scientific Reports · doi:10.1038/srep40263 · Cited by 55 · see citing works
Lin, Z., Chen, C., Yang, D., Ding, J., Wang, G., & Ren, H. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04002-1 · Cited by 49 · see citing works
Cerebrospinal fluid α‐synuclein contributes to the differential diagnosis of Alzheimer's disease
Shi, M., Tang, L., Toledo, J. B., Ginghina, C., Wang, H., Aro, P., Jensen, P. H., Weintraub, D., Chen‐Plotkin, A. S., Irwin, D. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.015 · Cited by 42 · see citing works
Self-citationWang, Z.-Y., Han, Z.-M., Liu, Q.-F., Tang, W., Ye, K., & Yao, Y.-Y. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000447 · Cited by 39 · see citing works
Kruse, N., Persson, S., Alcolea, D., Bahl, J. M. C., Baldeiras, I., Capello, E., Chiasserini, D., Bocchio Chiavetto, L., Emersic, A., Engelborghs, S., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.003 · Cited by 38 · see citing works
Wang, H., Stewart, T., Toledo, J. B., Ginghina, C., Tang, L., Atik, A., Aro, P., Shaw, L. M., Trojanowski, J. Q., Galasko, D. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171013 · Cited by 33 · see citing works
Self-citation
- Authors
- Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., Montine, T. J., Hancock, A. M., Hwang, H., Pan, C., Bradner, J., Kang, U. J., Jensen, P. H., & Zhang, J.
- Affiliations
- University of Washington (US)
- Oregon Health & Science University (US)
- University of California San Diego (US)
- Baylor College of Medicine (US)
- University of Chicago (US)
- Aarhus University (DK)
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-02-15
- Volume
- 133
- Issue
- 3
- Pages
- 713-726
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2842513
- OpenAlex
- W2033132890
- Cited by
- 615
- References
- 33
- Citations by year
- 2026: 12 · 2025: 22 · 2024: 21 · 2023: 24 · 2022: 33 · 2021: 32 · 2020: 41 · 2019: 44 · 2018: 44 · 2017: 38 · 2016: 49 · 2015: 51 · 2014: 54 · 2013: 48 · 2012: 44
- FWCI
- 28.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG 08671, AG 08017, AG 05136, R01AG033398, AG033398, P30AG008017, AG025327, P50AG008671, R01AG025327, P50AG005136)
- National Institute of Neurological Disorders and Stroke (P50NS062684, NS057567, NS060252, R01NS057567, R21NS060252, R01NS053919, NS062684)
- National Institute of Environmental Health Sciences (P42ES004696, ES004696)
- National Center for Research Resources (UL1RR025014)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Parkinson's disease, DJ-1, alpha-synuclein, cerebrospinal fluid biomarkers, Luminex multiplex assay, blood contamination, age-related variation, sensitivity and specificity, Alzheimer's disease comparison, disease severity
- MeSH terms
- Protein Deglycase DJ-1, Adult, Age Factors, Aged, Aged, 80 and over, Alzheimer Disease, Blood, Cerebrospinal Fluid, Female, Humans, Male, Middle Aged, Parkinson Disease, Sensitivity and Specificity, Severity of Illness Index, Sex Factors, Biomarkers, Oncogene Proteins, Intracellular Signaling Peptides and Proteins, alpha-Synuclein, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
